Method for preparing and detecting intermediate and corresponding isomer of afatinib

An enantiomer and afatinib technology, which is applied in the field of content detection of key intermediates and their enantiomers, can solve the problems of different adsorption and desorption capabilities, and large differences in substituents of key intermediates. , to achieve the effect of ensuring precision and accuracy and ensuring optical purity

Active Publication Date: 2017-02-22
SHINEWAY PHARMA GRP LTD
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The prior art only has a detection method for the enantiomer content of the finished product of Afatinib, and because the key intermediate substituents shown in Afatinib (Formula 1) and (Formula 2) are quite different, the two compounds The adsorption and desorption capabilities in the chromatographic column are different, which results in the detection method of the enantiomer of the finished product of afatinib cannot be used to detect the content of the enantiomer of its key intermediate, so due to "strict control In order to meet the needs of the optical purity of chiral raw materials and the reaction products of each step", it is necessary to develop a method suitable for detecting the enantiomer (formula 3) content of the key intermediate of afatinib (formula 2), so as to ensure that afatinib Optical purity of finished product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing and detecting intermediate and corresponding isomer of afatinib
  • Method for preparing and detecting intermediate and corresponding isomer of afatinib
  • Method for preparing and detecting intermediate and corresponding isomer of afatinib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Chromatographic conditions: use cellulose-tris(3,5-dimethylphenylcarbamate) as filler (reference column: LuxChiralCellulose-1 (250*4.6mm, 5μm)), column temperature is 25°C, Using n-hexane-isopropanol-acetonitrile (750:200:50) as the mobile phase, the flow rate is 0.9ml per minute, the detection wavelength is 260nm, and the analysis time is 30 minutes.

[0030] Detection method: take N4-(3-chloro-4-fluorophenyl)-7-[[(3S)-tetrahydro-3-furyl]oxy]-4,6-quinazoline diamine compound (formula 2) 10mg, accurately weighed, put in a 20ml measuring bottle, add isopropanol to dissolve and dilute to the mark, shake well, and use it as the test solution. Take an appropriate amount of N4-(3-chloro-4-fluorophenyl)-7-[[(3R)-tetrahydro-3-furyl]oxy]-4,6-quinazolinediamine compound (Formula 3) , add isopropanol to dissolve and quantitatively dilute to make a solution containing 2.5 μg per 1 ml, as the reference solution. Take 10 mg of the compound of formula 2 and 2 mg of the compound of ...

Embodiment 2

[0047] Chromatographic conditions: use cellulose-tris(3,5-dimethylphenylcarbamate) as filler (reference column: LuxChiralCellulose-1 (250*4.6mm, 5μm)), column temperature is 25°C, Using n-hexane-isopropanol-acetonitrile (700:250:50) as the mobile phase, the flow rate is 0.9ml per minute, the detection wavelength is 260nm, and the analysis time is 30 minutes.

[0048] Detection method: take N4-(3-chloro-4-fluorophenyl)-7-[[(3S)-tetrahydro-3-furyl]oxy]-4,6-quinazoline diamine compound (formula 2) 10mg, accurately weighed, put in a 20ml measuring bottle, add isopropanol to dissolve and dilute to the mark, shake well, and use it as the test solution. Take an appropriate amount of N4-(3-chloro-4-fluorophenyl)-7-[[(3R)-tetrahydro-3-furyl]oxy]-4,6-quinazolinediamine compound (Formula 3) , add isopropanol to dissolve and quantitatively dilute to make a solution containing 2.5 μg per 1 ml, as the reference solution. Take 10 mg of the compound of formula 2 and 2 mg of the compound of ...

Embodiment 3

[0061] Chromatographic conditions: use cellulose-tris(3,5-dimethylphenylcarbamate) as filler (reference column: LuxChiral Cellulose-1 (250*4.6mm, 5μm)), column temperature is 25°C , using n-hexane-isopropanol-acetonitrile (800:150:50) as the mobile phase, the flow rate is 0.9ml per minute, the detection wavelength is 260nm, and the analysis time is 30 minutes.

[0062] Detection method: take N4-(3-chloro-4-fluorophenyl)-7-[[(3S)-tetrahydro-3-furyl]oxy]-4,6-quinazoline diamine compound (formula 2) 10mg, accurately weighed, put in a 20ml measuring bottle, add isopropanol to dissolve and dilute to the mark, shake well, and use it as the test solution. Take an appropriate amount of N4-(3-chloro-4-fluorophenyl)-7-[[(3R)-tetrahydro-3-furyl]oxy]-4,6-quinazolinediamine compound (Formula 3) , add isopropanol to dissolve and quantitatively dilute to make a solution containing 2.5 μg per 1 ml, as the reference solution. Take 10 mg of the compound of formula 2 and 2 mg of the compound o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
separationaaaaaaaaaa
recovery rateaaaaaaaaaa
separationaaaaaaaaaa
Login to view more

Abstract

The invention discloses a method for simultaneously detecting a key intermediate (formula 2) and a corresponding isomer (formula 3) of afatinib. According to the method, isocratic elution is performed on a high performance liquid chromatograph; a chromatographic column which takes cellulose-tris(3,5-dimethyl phenylcarbamate) as a filling agent is adopted; a flow phase is a mixed solution of n-hexane, isopropyl alcohol and acetonitrile. Through the method, the key intermediate (formula 2) and the corresponding isomer (formula 3) of the afatinib can be effectively separated and detected, and the separation degree can reach 2.0 or higher.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a method for detecting the content of a key intermediate for preparing afatinib and its enantiomer. Background technique [0002] Chiral drugs refer to drugs composed of chiral compounds with pharmacological activity. Because the receptors or targets acted by drug molecules are chiral proteins and nucleic acid macromolecules composed of amino acids, nucleosides, membranes, etc. They have certain requirements on the spatial configuration (chirality) of the drug molecules bound to them. Therefore, the two enantiomers of chiral drugs often have significant differences in pharmacological activity, metabolic process, metabolic rate and toxicity in vivo. Illustrated by a famous incident in the 1960s: racemic thalidomide was a powerful sedative and antiemetic, especially suitable for use in early pregnancy reactions. But it was soon found to be an extremely potent terat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02
CPCG01N30/02
Inventor 许桂玲李志刚郝福巴晓雨张艳侠
Owner SHINEWAY PHARMA GRP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap